Standard BioTools Inc. (LAB) stock
LABNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 12/3085% below fair value
$0.71+0.06 (+8.60%)
Close on Nov 13, 2026Market cap $277.71MP/E 3.2Yield –
Standard BioTools price to book ratio
The price-to-book ratio is market cap divided by shareholders' equity.
Standard BioTools's price to book ratio was 0.5× on Nov 11, 2026, against 1.4× a year earlier. Over the last 5 years it ranged from 0.4× to 6.6×, with a median of 1.5×.
Price to Book Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 0.5× | −0.8 |
| 2025 | Dec 31, 2025 | 1.2× | −0.1 |
| 2024 | Dec 31, 2024 | 1.3× | −3.7 |
| 2022 | Jul 29, 2022 | 5.1× | +2.0 |
| 2021 | Dec 31, 2021 | 3.0× | +0.1 |
| 2020 | Dec 31, 2020 | 2.9× | +1.4 |
| 2019 | Dec 31, 2019 | 1.5× | −13.6 |
| 2018 | Dec 31, 2018 | 15.1× | +9.3 |
| 2017 | Dec 29, 2017 | 5.8× | +2.7 |
| 2016 | Dec 30, 2016 | 3.1× | +0.6 |
| 2015 | Dec 31, 2015 | 2.5× | −3.7 |
| 2014 | Dec 31, 2014 | 6.2× | −3.9 |
| 2013 | Dec 31, 2013 | 10.1× | +6.6 |
| 2012 | Dec 31, 2012 | 3.5× | −1.0 |
| 2011 | Dec 30, 2011 | 4.5× | – |
See a number that looks wrong?